Synthetic pharmacotherapy for lupus nephritis

References

• Kadmiel M, Cidlowski JA. Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci. 2013;34:518–530.
   PubMed Web of Science ®Google Scholar
• Granner DK, Wang JC, Yamamoto KR. Regulatory actions of glucocorticoid hormones: from organisms to mechanisms. Adv Exp Med Biol. 2015;872:3–31.
   PubMed Web of Science ®Google Scholar
• Ramamoorthy S, Cidlowski JA. Corticosteroids: mechanisms of action in health and disease. Rheum Dis Clin North Am. 2016;42:15–31.
   PubMed Web of Science ®Google Scholar
• Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol. 2008;4(10):525–533.
   PubMedGoogle Scholar
• Nahar J, Haam J, Chen C, et al. Rapid nongenomic glucocorticoid actions in male mouse hypothalamic neuroendocrine cells are dependent on the nuclear glucocorticoid receptor. Endocrinology. 2015;156(8):2831–2842.
   PubMed Web of Science ®Google Scholar
• Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013;72(8):1280–1286.
   PubMed Web of Science ®Google Scholar
• Moroni G, Raffiotta F, Ponticelli C. Remission and withdrawal of therapy in lupus nephritis. J Nephrol. 2016;29(4):559–565.
   PubMed Web of Science ®Google Scholar
• Reppert SM, Weaver DR. Molecular analysis of mammalian circadian rhythms. Annu Rev Physiol. 2001;63:647–676.
   PubMed Web of Science ®Google Scholar
• Debono M, Price JN, Ross RJ. Novel strategies for hydrocortisone replacement. Best Pract Res Clin Endocrinol Metab. 2009;23(2):221–232.
   PubMed Web of Science ®Google Scholar
• Sinha A, Bagga A. Pulse steroid therapy. Indian J Pediatr. 2008;75(10):1057–1066.
   PubMed Web of Science ®Google Scholar
• Tsai YG, Lee CY, Lin TY, et al. CD8⁺ Treg cells associated with decreasing disease activity after intravenous methylprednisolone pulse therapy in lupus nephritis with heavy proteinuria. Plos One. 2014;9(1):e81344.
   PubMed Web of Science ®Google Scholar
• Franchin G, Diamond B. Pulse steroids: how much is enough? Autoimmun Rev. 2006;5(2):111–113.
   PubMed Web of Science ®Google Scholar
• Veal GJ, Cole M, Chinnaswamy G, et al. Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin’s lymphoma. Eur J Cancer. 2016;55:56–64.
   PubMed Web of Science ®Google Scholar
• Faurschou M, Sorensen IJ, Mellemkjaer L, et al. Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol. 2008;35:100–105.
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D’Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69(1):61–64.
   PubMed Web of Science ®Google Scholar
• Yilmaz N, Emmungil H, Gucenmez S, et al. Incidence of cyclophosphamide-induced urotoxicity and protective effect of mesna in rheumatic diseases. J Rheumatol. 2015;42:1664–1666.
   Web of Science ®Google Scholar
• Meistrich ML. Male gonadal toxicity. Pediatr Blood Cancer. 2009;53:261–266.
   PubMed Web of Science ®Google Scholar
• Latta K, Von Schnakenburg C, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol. 2001;16:271–282.
   PubMed Web of Science ®Google Scholar
• Appenzeller S, Blatyta PF, Costallat LT. Ovarian failure in SLE patients using pulse cyclophosphamide: comparison of different regimes. Rheumatol Int. 2008;28:567–571.
   PubMed Web of Science ®Google Scholar
• Wetzels JF. Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis? Neth J Med. 2004;62(10):347–352.
   PubMed Web of Science ®Google Scholar
• Clowse ME, Behera MA, Anders CK, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt). 2009;18(3):311–319.
   PubMed Web of Science ®Google Scholar
• Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372:923–932.
   PubMed Web of Science ®Google Scholar
• Shang W, Ning Y, Xu X, et al. Incidence of Cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. Plos One. 2015;10:e0126016.
   PubMed Web of Science ®Google Scholar
• Hemminki K, Liu X, Ji J, et al. Origin of B-cell neoplasms in autoimmune disease. Plos One. 2016;11(6):e0158360.
   Google Scholar
• Skedgel C, Rayson D, Younis T. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer? Support Care Cancer. 2016;24(1):387–394.
   PubMed Web of Science ®Google Scholar
• Elion G. The purine path to chemotherapy. Science. 1989;244(4900):41–47.
   PubMed Web of Science ®Google Scholar
• Dewit O, Moreels T, Baert F, et al. Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients. Clin Biochem. 2011;44:1062–1066.
   PubMed Web of Science ®Google Scholar
• Roberts RL, Barclay ML. Update on thiopurine pharmacogenetics in inflammatory bowel disease. Pharmacogenomics. 2015;16:891–903.
   PubMed Web of Science ®Google Scholar
• Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43:329–335.
   PubMed Web of Science ®Google Scholar
• Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111:1133–1145.
   PubMed Web of Science ®Google Scholar
• Marinković G, Kroon J, Hoogenboezem M, et al. Inhibition of GTPase Rac1 in endothelium by 6-mercaptopurine results in immunosuppression in nonimmune cells: new target for an old drug. J Immunol. 2014;192(9):4370–4378.
   PubMed Web of Science ®Google Scholar
• Lennard L. Implementation of TPMT testing. Br J Clin Pharmacol. 2014;77:704–714.
   PubMed Web of Science ®Google Scholar
• Burchard PR, Abou Tayoun AN, Lefferts JA, et al. Development of a rapid clinical TPMT genotyping assay. Clin Biochem. 2014;47:126–129.
   PubMed Web of Science ®Google Scholar
• Musumba CO. Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy. Aliment Pharmacol Ther. 2013;38:1025–1037.
   PubMed Web of Science ®Google Scholar
• Weaver JL. Establishing the carcinogenic risk of immunomodulatory drugs. Toxicol Pathol. 2012;40:267–271.
   PubMed Web of Science ®Google Scholar
• Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis. Cochrane Database Syst Rev. 2007;(4):CD003982.
   Google Scholar
• Abd Rachman AN, Tett SE, Staatz CE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease. Clin Pharmacokinet. 2013;52:303–331.
   PubMed Web of Science ®Google Scholar
• Colom H, Lloberas N, Andreu F, et al. Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients. Kidney Int. 2014;85:1434–1443.
   PubMed Web of Science ®Google Scholar
• Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005;14(Suppl 1):s2–8.
   PubMed Web of Science ®Google Scholar
• Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886–1895.
   PubMed Web of Science ®Google Scholar
• Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford). 2010;49(1):128–140.
   PubMed Web of Science ®Google Scholar
• Matsui K, Shibagaki Y, Sasaki H, et al. Mycophenolate mofetil-induced agranulocytosis in a renal transplant recipient. Clin Exp Nephrol. 2010;14:637–640.
   PubMed Web of Science ®Google Scholar
• Wagner M, Earley AK, Webster AC, et al. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev. 2015;(12):CD007746.
   Google Scholar
• Manger B, Hiepe F, Schneider M, et al. Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a phase III, open-label, single-arm, multicenter study. Clin Exp Gastroenterol. 2015;8:205–213.
   PubMedGoogle Scholar
• Maes B, Oellerich M, Ceuppens JL, et al. A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener’s granulomatosis. Nephrol Dial Transplant. 2002;17:923–926.
   PubMed Web of Science ®Google Scholar
• Dun B, Sharma A, Teng Y, et al. Mycophenolic acid inhibits migration and invasion of gastric cancer cells via multiple molecular pathways. Plos One. 2013;8:e81702.
   PubMed Web of Science ®Google Scholar
• Crane GM, Powell H, Kostadinov R. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget. 2015;6(32):33849–33866.
   PubMed Web of Science ®Google Scholar
• Sampaio MS, Cho YW, Shah T, et al. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients. Transplantation. 2012;93(1):73–81.
   PubMed Web of Science ®Google Scholar
• De Jonge H, De Loor H, Verbeke K, et al. In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin Pharmacol Ther. 2012;92:366–375.
   PubMed Web of Science ®Google Scholar
• Shi YY, Hesselink DA, Van Gelder T. Pharmacokinetics and pharmacodynamics of immunosuppressive drugs in elderly kidney transplant recipients. Transplant Rev (Orlando). 2015;29:224–230.
   PubMedGoogle Scholar
• Singh A, Tejani A. Hyperlipidemia in children: the role of uremia, steroids and cyclosporine therapy. Nephron. 1996;74(3):529–535.
   PubMed Web of Science ®Google Scholar
• Hegazy SK, Adam AG, Hamdy NA, et al. Effect of active infection on cytochrome P450 mediated metabolism of cyclosporine in renal transplant patients. Transpl Infect Dis. 2015;17:350–360.
   PubMed Web of Science ®Google Scholar
• Vanhove T, Annaert P, Kuypers DR. Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metab Rev. 2016;48:88–112.
   PubMed Web of Science ®Google Scholar
• Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplant Proc. 2004;36(2 Suppl):25S–32S.
   PubMed Web of Science ®Google Scholar
• Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013;65(9):2368–2379.
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther. 2012 7;14(1):R33.
   PubMed Web of Science ®Google Scholar
• Furie R, Nicholls K, Cheng TT, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 2014;66(2):379–389.
   PubMed Web of Science ®Google Scholar
• Azzi JR, Sayegh MH, Mallat SG. Calcineurin inhibitors: 40 years later, can’t live without. J Immunol. 2013;191(12):5785–5791.
   PubMed Web of Science ®Google Scholar
• Moroni G, Doria A, Ponticelli C. Cyclosporine (CsA) in lupus nephritis: assessing the evidence. Nephrol Dial Transplant. 2009;24(1):15–20.
   PubMed Web of Science ®Google Scholar
• Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev. 2010;(1):CD007893.
   Google Scholar
• Taler SJ, Textor SC, Canzanello VJ, et al. Cyclosporin-induced hypertension, incidence, pathogenesis and management. Drug Safety. 1999;20:437–449.
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Cucchiari D, Graziani G. Hypertension in kidney transplant recipients. Transpl Int. 2011;24(6):523–533.
   PubMed Web of Science ®Google Scholar
• Textor SC, Taler SJ, Canzanello VJ, et al. Posttransplantation hypertension related to calcineurin inhibitors. Liver Transpl. 2000;6(5):521–530.
   PubMed Web of Science ®Google Scholar
• Azziz R. The evaluation and management of hypertrichosis. Obstet Gynecol. 2003;101:995–1007.
   PubMed Web of Science ®Google Scholar
• Chand DH, Quattrocchi J, Poe SA, et al. Trial of metronidazole vs. azithromycin for treatment of cyclosporine-induced gingival overgrowth. Pediatr Transplant. 2004;8(1):60–64.
   PubMed Web of Science ®Google Scholar
• Suk HY, Zhou C, Yang TT, et al. Ablation of calcineurin Aβ reveals hyperlipidemia and signaling cross-talks with phosphodiesterases. J Biol Chem. 2013;288:3477–3488.
   PubMed Web of Science ®Google Scholar
• Fuhrmann A, Lopes P, Sereno J, et al. Molecular mechanisms underlying the effects of cyclosporin A and sirolimus on glucose and lipid metabolism in liver, skeletal muscle and adipose tissue in an in vivo rat model. Biochem Pharmacol. 2014;88:216–228.
   PubMed Web of Science ®Google Scholar
• Savvidaki E, Koukoulaki M, Benou A, et al. Ezetimibe is effective in the treatment of persistent hyperlipidemia of renal allograft recipients. Clin Nephrol. 2011;75(2):107–112.
   PubMed Web of Science ®Google Scholar
• Suthanthiran M, Hojo M, Maluccio M, et al. Post-transplantation malignancy: a cell autonomous mechanism with implications for therapy. Trans Am Clin Climatol Assoc. 2009;120:369–378.
   PubMedGoogle Scholar
• Malvezzi P, Rostaing L. The safety of calcineurin inhibitors for kidney-transplant patients. Expert Opin Drug Saf. 2015;14(10):1531–1546.
   PubMed Web of Science ®Google Scholar
• Lalan S, Abdel-Rahman S, Gaedigk A, et al. Effect of CYP3A5 genotype, steroids, and azoles on tacrolimus in a pediatric renal transplant population. Pediatr Nephrol. 2014;29(10):2039–2049.
   PubMed Web of Science ®Google Scholar
• Tang JT, Andrews LM, Van Gelder T, et al. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. Expert Opin Drug Metab Toxicol. 2016;12:555–565.
   PubMed Web of Science ®Google Scholar
• Kim JS, Aviles DH, Silverstein DM, et al. Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant. 2005;9:162–169.
   PubMed Web of Science ®Google Scholar
• Minguillón J, Morancho B, Kim SJ, et al. Concentrations of cyclosporin A and FK506 that inhibit IL-2 induction in human T cells do not affect TGF-beta1 biosynthesis, whereas higher doses of cyclosporin A trigger apoptosis and release of preformed TGF-beta1. J Leukoc Biol. 2005;77:748–758.
   PubMed Web of Science ®Google Scholar
• Chiasson VL, Jones KA, Kopriva SE, et al. Endothelial cell transforming growth factor-β receptor activation causes tacrolimus-induced renal arteriolar hyalinosis. Kidney Int. 2012;82:857–866.
   PubMed Web of Science ®Google Scholar
• Øzbay LA, Smidt K, Mortensen DM, et al. Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells. Br J Pharmacol. 2011;162:136–146.
   PubMed Web of Science ®Google Scholar
• Li Z, Sun F, Zhang Y, et al. Tacrolimus induces insulin resistance and increases the glucose absorption in the jejunum: a potential mechanism of the diabetogenic effects. Plos One. 2015;10:e0143405.
   PubMed Web of Science ®Google Scholar
• Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. Bmj. 2005;331:810.
   PubMed Web of Science ®Google Scholar
• Savvidaki E, Papachristou E, Kazakopoulos P, et al. Gastrointestinal disorders after renal transplantation. Transplant Proc. 2014;46:3183–3186.
   PubMed Web of Science ®Google Scholar
• Tran D, Vallée M, Collette S, et al. Conversion from twice-daily to once-daily extended-release tacrolimus in renal transplant recipients: 2-year results and review of the literature. Exp Clin Transplant. 2014;12(4):323–327.
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Campise R. Neurological complications in kidney transplant recipients. J Nephrol. 2005;18:521–528.
   PubMed Web of Science ®Google Scholar
• Manzarbeitia C, Reich DJ, Rothstein KD, et al. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients. Liver Transpl. 2001;7(2):93–99.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215–1226.
   PubMed Web of Science ®Google Scholar
• Iaccarino L, Bartoloni E, Carli L, et al. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. Clin Exp Rheumatol. 2015;33(4):449–456.
   PubMed Web of Science ®Google Scholar
• Moroni G, Raffiotta F, Trezzi B, et al. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology (Oxford). 2014;53(9):1570–1577.
   PubMed Web of Science ®Google Scholar
• Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus. 2013;22(1):63–72.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011;70:1905–1913.
   PubMed Web of Science ®Google Scholar
• Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(11):1909–1916.
   PubMed Web of Science ®Google Scholar
• Jayne D, Chan TM, Barkay H, et al. A randomized controlled study of laquinimod in active lupus nephritis patients in combination with standard of care. Ann Rheum Dis. 2013;72:164.
   Google Scholar
• Alexander T, Sarfert R, Klotsche J, et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis. 2015;74(7):1474–1478.
   PubMed Web of Science ®Google Scholar
• Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 2012;64(11):3660–3665.
   PubMed Web of Science ®Google Scholar
• Furie R, Toder K, Zapantis E. Lessons learned from the clinical trials of novel biologics and small molecules in lupus nephritis. Semin Nephrol. 2015;35(5):509–520.
   PubMed Web of Science ®Google Scholar
• Moroni G, Quaglini S, Gallelli B, et al. Progressive improvement of patient and renal survival and reduction of morbidity over time in patients with lupus nephritis (LN) followed for 20 years. Lupus. 2013;22(8):810–818.
   PubMed Web of Science ®Google Scholar
• Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1778.
   PubMed Web of Science ®Google Scholar
• Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797–808.
   PubMed Web of Science ®Google Scholar
• Mina R, Von Scheven E, Ardoin SP, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64(3):375–383.
   PubMed Web of Science ®Google Scholar
• Wilhelmus S, Bajema IM, Bertsias GK, et al. Lupus nephritis management guidelines compared. Nephrol Dial Transplant. 2016;31(6):904–913.
   PubMed Web of Science ®Google Scholar
• Durcan L, Clarke WA, Magder LS, et al. Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheumatol. 2015;42(11):2092–2097.
   PubMed Web of Science ®Google Scholar
• Khamashta MA, Buchanan NM, Hughes GR. The use of hydroxychloroquine in lupus pregnancy: the British experience. Lupus. 1996;5(Suppl 1):S65–6.
   PubMed Web of Science ®Google Scholar
• Ponticelli C. New therapies for lupus nephritis. Clin J Am Soc Nephrol. 2006;1(4):863–868.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Latinis K, et al. LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215–1226.
   PubMed Web of Science ®Google Scholar